Post-Operative Pain - Pipeline Review, H1 2019

Date: April 23, 2019
Pages: 265
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P05D43870BFEN
Leaflet:

Download PDF Leaflet

Post-Operative Pain - Pipeline Review, H1 2019
Post-Operative Pain - Pipeline Review, H1 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Pipeline Review, H1 2019, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 8, 22, 9, 4, 32, 2 and 1 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 3 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Post-Operative Pain - Overview
Post-Operative Pain - Therapeutics Development
Post-Operative Pain - Therapeutics Assessment
Post-Operative Pain - Companies Involved in Therapeutics Development
Post-Operative Pain - Drug Profiles
Post-Operative Pain - Dormant Projects
Post-Operative Pain - Discontinued Products
Post-Operative Pain - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Post-Operative Pain, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Post-Operative Pain - Pipeline by Abide Therapeutics Inc, H1 2019
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, H1 2019
Post-Operative Pain - Pipeline by Adynxx Inc, H1 2019
Post-Operative Pain - Pipeline by AngioChem Inc, H1 2019
Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2019
Post-Operative Pain - Pipeline by Apsen Farmaceutica SA, H1 2019
Post-Operative Pain - Pipeline by Cadila Healthcare Ltd, H1 2019
Post-Operative Pain - Pipeline by Camurus AB, H1 2019
Post-Operative Pain - Pipeline by Cara Therapeutics Inc, H1 2019
Post-Operative Pain - Pipeline by Cellix Bio Pvt Ltd, H1 2019
Post-Operative Pain - Pipeline by CerSci Therapeutics Inc, H1 2019
Post-Operative Pain - Pipeline by Cytogel Pharma LLC, H1 2019
Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, H1 2019
Post-Operative Pain - Pipeline by DURECT Corp, H1 2019
Post-Operative Pain - Pipeline by Esteve Pharmaceuticals SA, H1 2019
Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H1 2019
Post-Operative Pain - Pipeline by EyeGate Pharmaceuticals Inc, H1 2019
Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp, H1 2019
Post-Operative Pain - Pipeline by Grunenthal GmbH, H1 2019
Post-Operative Pain - Pipeline by Heron Therapeutics Inc, H1 2019
Post-Operative Pain - Pipeline by Immupharma Plc, H1 2019
Post-Operative Pain - Pipeline by Innocoll AG, H1 2019
Post-Operative Pain - Pipeline by Insys Therapeutics Inc, H1 2019
Post-Operative Pain - Pipeline by Ionis Pharmaceuticals Inc, H1 2019
Post-Operative Pain - Pipeline by iX Biopharma Ltd, H1 2019
Post-Operative Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2019
Post-Operative Pain - Pipeline by Liquidia Technologies Inc, H1 2019
Post-Operative Pain - Pipeline by Lumosa Therapeutics Co Ltd, H1 2019
Post-Operative Pain - Pipeline by MedinCell SA, H1 2019
Post-Operative Pain - Pipeline by Medtronic Plc, H1 2019
Post-Operative Pain - Pipeline by Mundipharma International Ltd, H1 2019
Post-Operative Pain - Pipeline by Neumentum Inc, H1 2019
Post-Operative Pain - Pipeline by Novartis AG, H1 2019
Post-Operative Pain - Pipeline by Ocular Therapeutix Inc, H1 2019
Post-Operative Pain - Pipeline by Pacira Pharmaceuticals Inc, H1 2019
Post-Operative Pain - Pipeline by PainReform Ltd, H1 2019
Post-Operative Pain - Pipeline by Pharmaleads SA, H1 2019
Post-Operative Pain - Pipeline by PhytoHealth Corp, H1 2019
Post-Operative Pain - Pipeline by PixarBio Corp, H1 2019
Post-Operative Pain - Pipeline by PolyPid Ltd, H1 2019
Post-Operative Pain - Pipeline by RaQualia Pharma Inc, H1 2019
Post-Operative Pain - Pipeline by Recro Pharma Inc, H1 2019
Post-Operative Pain - Pipeline by Rottapharm Biotech Srl, H1 2019
Post-Operative Pain - Pipeline by Serina Therapeutics Inc, H1 2019
Post-Operative Pain - Pipeline by Shijiazhuang Yiling Pharmaceutical Co Ltd, H1 2019
Post-Operative Pain - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H1 2019
Post-Operative Pain - Pipeline by SiteOne Therapeutics Inc, H1 2019
Post-Operative Pain - Pipeline by SteadyMed Therapeutics Inc, H1 2019
Post-Operative Pain - Pipeline by Taiwan Liposome Co Ltd, H1 2019
Post-Operative Pain - Pipeline by Teikoku Pharma USA Inc, H1 2019

LIST OF FIGURES

Number of Products under Development for Post-Operative Pain, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

COMPANIES MENTIONED

Abide Therapeutics Inc
AcelRx Pharmaceuticals Inc
Adynxx Inc
AngioChem Inc
Aoxing Pharmaceutical Company Inc
Apsen Farmaceutica SA
Cadila Healthcare Ltd
Camurus AB
Cara Therapeutics Inc
Cellix Bio Pvt Ltd
CerSci Therapeutics Inc
Cytogel Pharma LLC
Dompe Farmaceutici SpA
DURECT Corp
Esteve Pharmaceuticals SA
Eupraxia Pharmaceuticals Inc
EyeGate Pharmaceuticals Inc
Fujimoto Pharmaceutical Corp
Grunenthal GmbH
Heron Therapeutics Inc
Immupharma Plc
Innocoll AG
Insys Therapeutics Inc
Ionis Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Liquidia Technologies Inc
Lumosa Therapeutics Co Ltd
MedinCell SA
Medtronic Plc
Mundipharma International Ltd
Neumentum Inc
Novartis AG
Ocular Therapeutix Inc
Pacira Pharmaceuticals Inc
PainReform Ltd
Pharmaleads SA
PhytoHealth Corp
PixarBio Corp
PolyPid Ltd
RaQualia Pharma Inc
Recro Pharma Inc
Rottapharm Biotech Srl
Serina Therapeutics Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
SteadyMed Therapeutics Inc
Taiwan Liposome Co Ltd
Teikoku Pharma USA Inc
Trevena Inc
Xigen SA
YiChang Humanwell Pharmaceutical Co Ltd
Skip to top


Cancer Pain - Pipeline Review, H1 2018 US$ 2,000.00 Apr, 2018 · 119 pages
Osteoarthritis Pain - Pipeline Review, H1 2017 US$ 2,000.00 May, 2017 · 202 pages
Post-Operative Pain - Pipeline Review, H2 2018 US$ 2,000.00 Jul, 2018 · 232 pages

Ask Your Question

Post-Operative Pain - Pipeline Review, H1 2019
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: